ALEXIOS MATRALIS
Chief Medicinal Chemist
​​
Dr. Alexios N. Matralis holds a B.Sc. in Chemistry from the University of Patras and both an M.Sc. and Ph.D. in Medicinal Chemistry from the University of Athens. He has over fifteen years of research experience in the development of bioactive molecules targeting multifactorial human diseases such as atherosclerosis, type 2 diabetes, cancer, chronic inflammatory disorders, and malaria.
Following his Ph.D., he conducted postdoctoral research at McGill University in Montréal, Canada, where he developed a novel series of senescence-inducing agents for pancreatic cancer, which attracted interest from Merck for further development. In 2017, he joined GlaxoSmithKline as a senior researcher, where he contributed to the development of novel fast-acting antimalarial compounds, currently undergoing advanced preclinical studies. In 2018, Alexios joined BSRC “Alexander Fleming” as a Stavros Niarchos Research Fellow where he led research programs focused on small molecule drug discovery targeting fibrosis, cancer, and inflammatory diseases, including an Individual Research Grant from the Hellenic Foundation for Research and Innovation.
Since 2025, Alexios serves as Chief Medicinal Chemist at INOLYSIS, overseeing the design and development of novel therapeutics targeting fibroblast-driven pathologies.
OUR TEAM
.jpg)
Founder and President
GEORGE KOLLIAS
Founder and President
​
George Kollias is Member of the Academy of Athens, Professor of Physiology at the Medical School, UoA, and Research Professor at the BSRC "Alexander Fleming". His lab provided proof of principle preclinical studies that led to the development of anti-TNF therapies for Rheumatoid arthritis. He has pioneered genetic approaches to study the function of cytokine signaling in animal models of human diseases and contributed knowledge on the molecular and cellular mechanisms driving chronic inflammation, autoimmunity and cancer. More recently, the lab made pioneering contributions to uncovering the pivotal role of fibroblasts in pathophysiology, instigating new therapeutic opportunities for chronic inflammatory and fibrotic diseases. His work has received 49K citations and an h-index of 100 (Source: Google Scholar). His laboratory is supported by several competitive grants from national sources and the European Commission, and has been awarded with two (2014, 2022) Advanced Grants from the European Research Council (ERC). GK developed the National Research Infrastructures Infrafrontier.GR/Phenotypos from BSRC Fleming, and pMedGR from the Medical School of Athens. In 2006 he founded Fleming’s first CRO biotech spinoff, Biomedcode Hellas SA, and in 2025 he founded INOLYSIS, which focuses on the development of therapeutics for fibrosis. He is Member of the European Molecular Biology Organization (EMBO). He was elected and served as President and Director of the Biomedical Sciences Research Center “Alexander Fleming” (2002-2010 & 2016-2020). In 2014, he was awarded the Carol-Nachman Award for Rheumatology. GK is Director of the International Graduate Program in "Molecular Biomedicine" running at the Medical School and BSRC Fleming.
ALEXIOS MATRALIS
Chief Medicinal Chemist
ALEXIOS MATRALIS
Chief Medicinal Chemist
​​
Alexios N. Matralis holds a B.Sc. in Chemistry from the University of Patras and both an M.Sc. and Ph.D. in Medicinal Chemistry from the University of Athens. He has over fifteen years of research experience in the development of bioactive molecules targeting multifactorial human diseases such as atherosclerosis, type 2 diabetes, cancer, chronic inflammatory disorders, and malaria.
Following his Ph.D., he conducted postdoctoral research at McGill University in Montréal, Canada, where he developed a novel series of senescence-inducing agents for pancreatic cancer, which attracted interest from Merck for further development. In 2017, he joined GlaxoSmithKline as a senior researcher, where he contributed to the development of novel fast-acting antimalarial compounds, currently undergoing advanced preclinical studies. In 2018, Alexios joined BSRC “Alexander Fleming” as a Stavros Niarchos Research Fellow where he led research programs focused on small molecule drug discovery targeting fibrosis, cancer, and inflammatory diseases, including an Individual Research Grant from the Hellenic Foundation for Research and Innovation.
Since 2025, Alexios serves as Chief Medicinal Chemist at INOLYSIS, overseeing the design and development of novel therapeutics targeting fibroblast-driven pathologies.
ANASTASIA MPAKALI
Lead Research Scientist
ANASTASIA MPAKALI
Lead Research Scientist
​​
Anastasia Mpakali holds a B.Sc. in Biology and an M.Sc. and Ph.D. in Molecular Medicine from the National and Kapodistrian University of Athens, with her doctoral research conducted in collaboration with BSRC “Alexander Fleming”. She has extensive expertise in drug development, particularly in the design, screening, and mechanistic evaluation of small-molecule inhibitors targeting immune and neuroregulatory pathways.
With over 12 years of postdoctoral research experience, Anastasia has led impactful projects at the National Centre for Scientific Research “Demokritos”, including structural and functional studies of aminopeptidases (ERAP1/2, IRAP) and the development of nanomolar inhibitors for these targets. Her research, supported by competitive funding such as the HFRI/ELIDEK ARIA award, bridges atomic-resolution enzymology with translational drug design.
In 2024, she joined the Kollias Lab at BSRC “Alexander Fleming” as a postdoctoral fellow, leading the group’s translational R&D efforts to identify novel therapeutics against inflammation and fibrosis.
Since 2025, she serves as Lead Research Scientist at INOLYSIS, driving target validation, assay development, and screening strategies for the company’s fibroblast-targeted drug discovery pipeline.
PIYI PAPADAKI
Chief Operations Manager
PIYI PAPADAKI
Chief Operations Manager
​​
Piyi Papadaki holds a B.Sc. in Chemistry from the University of Athens and an M.Sc. and Ph.D. in Molecular Biology from the Department of Biology at New York University (NYU), USA. She conducted postdoctoral research as a Marie Curie Fellow at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. In 2008, she returned to Greece to join the group of George Kollias at BSRC Fleming, where she undertook the setup, management and coordination of major research, innovation, and infrastructure projects. From 2016 to 2020, she served as Head of the President’s Office and Grants Office at BSRC Fleming, overseeing organizational planning and cross-functional coordination across administrative and research units, while supporting executive decision-making and strategic development initiatives. She also provides consultancy to private-sector organizations, offering expertise in funding acquisition, human resources and intellectual property management, business development and commercialization strategy.
Since 2025, she serves as Chief Operations Manager at INOLYSIS, where she supports strategic planning and operational execution of the company’s research and innovation activities.